ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
08 nov. 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
30 oct. 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey,...
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
25 oct. 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial...
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
02 oct. 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares New 1-mL size furthers ANI’s commitment to...
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
18 sept. 2023 16h05 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey,...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
12 sept. 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Sept. 12, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
28 août 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for...
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24 août 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey,...
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
23 août 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and...
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
09 août 2023 06h50 HE
|
ANI Pharmaceuticals, Inc.
Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and...